Safety Data from the VISION Trial

In an interview with Targeted Oncology, Pedro Barata, MD, MSc, discussed the current therapies available, unmet needs, and ongoing studies for patients with metastatic prostate cancer.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tanya B. Dorff, and participants, discussed the case of a patient with metastatic castration-resistant prostate cancer who has already received enzalutamide and docetaxel.

In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.

Significant differences in the incidence of genitourinary events, depression, and ischemic and thrombotic events were observed based on race among patients with prostate cancer after receiving androgen deprivation therapy.

It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.